Immunic, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for IMUX, updated each market day.
IMUX AI Sentiment
AI predicts Immunic, Inc. Common Stock stock is likely to increase over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Immunic, Inc. Common Stock
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.
Sector
Exchange
Market Cap
$168,299,624
Cap Tier
Employees
92
Headquarters
NEW YORK, X1
Listed Since
April 17, 2014
Website
IMUX Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
IMUX Volatility
Immunic, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
